Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$10.6M
3M shares
52-week range
$2.12 – $42.00
2% from low
Exchange
NASDAQ
CS
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
www.icecure-medical.comNo one on the platform currently holds ICCM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 10,900 | $12.0K |
| Execution date | Ratio |
|---|---|
| 2026-06-04 | 1-for-30reverse |
No one on the platform has traded ICCM yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/235/icecure-highlights-two-new-peer-reviewed-publications-supporting-cryoablation-in-breast-cancer-treatment-de-escalation
View on StockTwits ↗$ICCM as expected, lost a lot of money, can't sell anything but stock.
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-12-icecure-medical-ltd-stock/ $ICCM IceCure Medical Earnings Transcript
View on StockTwits ↗@StocktwitsEarnings $ICCM according to google, GAAP EPS is profit after all cost and expenses, so how can they lose money and have GAAP EPS of 1.63 ?
View on StockTwits ↗$ICCM Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.63 up 191.06% YoY • Reported revenue of $0.91M up 72.76% YoY
View on StockTwits ↗$ICCM IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
View on StockTwits ↗$ICCM Earnings day after tomorrow. Should be a nice upside surprise based on the company’s previous PR’s. Hopefully will be a catalyst to increase both the price and trading liquidity besides generating some institutional interest.
View on StockTwits ↗$ICCM Remember although this is a FDA approved treatment for 70 plus year olds and people who can't have surgery the stock is down 90% after approval, 99% for all time, and the management SEEMED to actively participate in driving it down to near zero recently so they could do a reverse split and a pump and dump, so don't think they care about shareholders or the stock price, they just want to sell shares by any means possible. That's why it's where it is and why no one trust them.
View on StockTwits ↗$ICCM Never seems to hold value, seems like people don't trust them
View on StockTwits ↗$CLRO $PAVS $CELZ They're on fire today 🔥🔥🔥 $ICCM target 🎯
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6M | +87.3% | $-5.67 | $-7.45–$-4.13 | — | 2 |
| 2027 | $13M | +97.0% | $-3.87 | $-5.09–$-2.82 | — | 2 |
| 2028 | $26M | +108.1% | $-1.68 | $-2.10–$-1.26 | — | 2 |
| 2029 | $42M | +61.7% | $0.14 | $0.10–$0.18 | 22.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $-1.52 | $-3.11 | -104.6% |
| 2026-05-12 | $-0.90 | $-1.80 | -100.0% |
| 2026-03-17 | $-1.20 | $-1.80 | -50.0% |
| 2025-11-19 | $-0.05 | $-0.06 | -20.0% |
| 2025-08-13 | $-0.06 | $-0.06 | +0.0% |
| 2025-05-28 | $-0.08 | $-0.06 | +25.0% |
| 2025-03-27 | $-0.07 | $-0.08 | -8.7% |
| 2024-11-26 | $-0.07 |
| $-0.08 |
| -14.3% |
| $54M |
| — |
| MDCXMedicus Pharma Ltd. Common Stock | $0.31 | -11.61% | $7M | — |
| PETSPetMed Express, Inc. | $1.84 | -9.25% | $39M | — |
Source: Financial Modeling Prep · peers by sector/industry